Generate Biomedicines, Inc. GENB
10.58 USD +0.20 (+1.90%)
As ofNov 19, 2026, 11:43 AM EST
10.24 Day range 10.84
9.68 52-week range 22.67
- YTD
- -16.38%
- 1 year
- -16.38%
News
benzinga.com Morgan Stanley Maintains Overweight on Generate Biomedicines, Lowers Price Target to $21 Morgan Stanley analyst Sean Laaman maintains Generate Biomedicines (NASDAQ:GENB) with a Overweight and lowers the price target from $22 to $21.
benzinga.com Generate Biomedicines Q3 EPS $(0.68) Misses $(0.59) Estimate, Sales $4.220M Miss $7.750M Estimate Generate Biomedicines (NASDAQ:GENB) reported quarterly losses of $(0.68) per share which missed the analyst consensus estimate of $(0.59) by 15.25 percent. This is a 65.48 percent increase over…
globenewswire.com Generate Biomedicines Reports Third Quarter 2026 Financial Results and Provides Business Update GB-0895 is being evaluated in two Phase 3 severe asthma studies for dosing twice a year A single dose of GB-0895 produced sustained pharmacological activity for at least six months in COPD Zealand…
